Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
07:59am, Sunday, 01'st Feb 2026
Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset
SG Americas Securities LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPN
04:56am, Sunday, 25'th Jan 2026
SG Americas Securities LLC decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 51.7% in the undefined quarter, according to the company in its most recent 13F filing with the Se
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $61.60 Average Price Target from Analysts
04:36am, Wednesday, 14'th Jan 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received an average recommendation of "Hold" from the seven analysts that are covering the firm, MarketBeat Ratings reports. One equ
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $31,552.40 in Stock
05:19am, Monday, 22'nd Dec 2025
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) VP Padmanabh Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an av
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $63.25 Consensus PT from Brokerages
04:44am, Saturday, 20'th Dec 2025
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has been assigned an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports.
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
11:35pm, Monday, 15'th Dec 2025
Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
03:57pm, Monday, 08'th Dec 2025
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
04:05pm, Wednesday, 03'rd Dec 2025
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 1,161 Shares of Supernus Pharmaceuticals, Inc. $SUPN
03:59am, Thursday, 27'th Nov 2025
Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 8.8% in the undefined quarter, according to its most recen
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
04:06pm, Friday, 21'st Nov 2025
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
02:15am, Friday, 21'st Nov 2025
Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on November 18th, the Representative disclosed that
Bank of New York Mellon Corp Purchases 11,877 Shares of Supernus Pharmaceuticals, Inc. $SUPN
03:40am, Wednesday, 19'th Nov 2025
Bank of New York Mellon Corp raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 3.1% in the second quarter, according to its most recent 13F filing with the Securities a
Envestnet Asset Management Inc. Increases Stake in Supernus Pharmaceuticals, Inc. $SUPN
04:34am, Monday, 17'th Nov 2025
Envestnet Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 50.2% during the undefined quarter, according to the company in its most recent Form 1
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
04:05pm, Wednesday, 12'th Nov 2025
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
12:36am, Wednesday, 05'th Nov 2025
Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & C
